A biomarker test now decides who enters a precision medicine trial, yet results often go unused and assays are not ready when screening opens.
|Articles|September 14, 2017
MedSource Expands Footprint, Adds New Service Line
Advertisement
MedSource is the Houston-based clinical research organization that has seen a number of growth-related milestones in the past year including its new service offering. With this in place, the new service line will be accompanied by a new department as well that will allow MedSource to provide their expertise throughought the whole drug development process.
Read the full release
Advertisement
Related to this article
In today's ACT Brief, we examine proportionate analysis frequency in RBQM, how to build trust into real-world evidence foundations for cancer trials, and how rare disease developers monetize regulatory success.
Real-time RBQM requires proportionate analysis frequency matched to data arrival and issue criticality, not continuous reanalysis, because signal churn from over-frequent runs creates alert fatigue and operational noise that obscures meaningful deterioration.
In this video interview, Saamir Pasha and Carole Berini, PhD, of Ontada, explain how building trust into the data foundation—through source lineage, standardization, and reconciliation—is what makes reliable real-world evidence generation in oncology possible.
In today's ACT Brief, we examine how AI surfaces design flaws before enrollment, why site training readiness depends on learning science, and the priorities defining next-generation weight-loss therapies.
Site training effectiveness depends on readiness at first-patient-in, requiring learning-science design principles around performance focus, cognitive load reduction, progressive sequencing, and spaced retrieval practice rather than training completion metrics or content volume.
In this Q&A, Claire Riches, VP of clinical solutions at Citeline, discusses how AI is transforming endpoint selection and protocol pressure-testing, what data inputs matter most for realistic enrollment planning, and why the tools are more accessible than most sponsors assume.
In today's ACT Brief, we examine the FDA's multi-domain transparency priorities, why radiopharmaceutical trials need redesigned infrastructure, and how AI can make enrollment more predictable.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Using AI to Design Better Trials Before the First Patient Enrolls: Q&A with Claire Riches, Citeline
2
What It Takes to Harmonize AI Across Fragmented Oncology Health Systems
3
Real-Time Data, Right-Time Decisions: Rethinking Analysis Frequency in RBQM
4
ACT Brief: AI and Protocol Design, Site Training Readiness, and GLP-1 Unmet Needs
5